ICGEB & Sun Pharma announce a new exclusive collaboration to develop novel dengue vaccine for India & Global markets

 


Novel Dengue Vaccine development to focus on its suitability for all population including affected and non-affected paediatric, adults and travellers

Partnership follows extensive & expert due-diligence of global dengue vaccine programs

Sun Pharma to explore global commercialisation opportunities for the vaccine across India, Emerging Markets, Western Europe, Japan and USA

NEW DELHI, OCTOBER 19, 2016

The ICGEB and Sun Pharmaceutical Industries today announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans. ICGEB has developed a tailored recombinant virus-like-particle (VLP) based tetravalent dengue vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes.

ICGEB has conducted pre-clinical studies over the past seven years and developed the existing Know-How and Patents for this dengue vaccine candidate. This is the second collaboration between Sun Pharma and ICGEB focusing on dengue. The first one announced in May 2016 was related to the development of a botanical drug for treatment of Dengue. The current collaboration is focussed on developing a novel, safe and effective vaccine for the prevention of dengue.

Dr. Salunke, Director, ICGEB New Delhi stated that despite recent approval of a dengue vaccine and several candidates being at advance stage of clinical trials, the development of a safe, affordable and efficacious dengue vaccine still faces major challenges. He further stated "I am pleased that the Dengue Vaccine Development program led by Dr. Navin Khanna at ICGEB is now proceeding to clinical development phase with Sun Pharma. The initial support from DBT and subsequent funding from Wellcome Trust has enabled ICGEB to bring this vaccine candidate at the stage it is today. We acknowledge the continued support of DBT and Wellcome Trust for these efforts at ICGEB. Our pre-clinical data is very encouraging and this could be an ideal dengue vaccine candidate for all target populations."

Commenting on the new collaboration signed with ICGEB, Mr. Kirti Ganorkar, Executive VP & Head, Global Business Development, Sun Pharma, said, “Our new collaboration with ICGEB for developing an affordable dengue vaccine is part of our broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world. Our decision to partner with ICGEB on dengue vaccine program followed extensive due diligence and expert consultations on existing dengue vaccine programs globally.”

According to the agreement signed today, Sun Pharma will fund and support further development of the vaccine candidate and existing ICGEB Know-How and Patents. ICGEB will grant Sun Pharma exclusive rights and licenses for development and commercialisation of this vaccine globally. ICGEB will receive pre-defined royalty & milestone payments. A joint development committee, comprising members of both the organisations, will be established to provide oversight to the dengue vaccine development program.

 Thanks also to funding from DBT and Wellcome Trust (photo at: https://wellcome.ac.uk/)
 Thanks also to funding from DBT and Wellcome Trust (photo at: https://wellcome.ac.uk/)

Press Releases: Sun Pharma

28 October 2016
NDTV Indian Scientists Develop Breakthrough Dengue Drug

India Today: Indian Scientists develop Dengue drug

20 October 2016
ABLE Association of Biotechnology Led Enterprises: Sun Pharma collaborates with ICGEB to develop dengue vaccine for Indian markets
The Financial Express: Sun Pharma, ICGEB tie up to develop vaccine for dengue
The Indian Express: Sun Pharma, ICGEB ties up to develop dengue vaccine
Infloria: Sun Pharma, ICGEB tie up to develop dengue vaccine
Live mint: Sun Pharma and ICGEB to develop new vaccine
Mag series: Sun Pharma signs deal with ICGEB to develop novel dengue vaccine
Mini Market: Sun Pharma, ICGEB ink pact to develop novel dengue vaccine
Money control: Sun Pharma, ICGEB tie up to develop dengue vaccine
News js: ICGEB and Sun Pharma
Real Time news: Sun pHarma to get dengue vaccine technology from ICGEB
Ten News: Sun Pharma and ICGEB announces collaboration to develop novel dengue vaccine
The Economic Times: Sun Pharma partners ICGEB to develop safer, cheaper dengue vaccine
Tiger capital of India: Sun Pharma and ICGEB to develop novel vaccine dengue
The Times of India: Sun Pharma in dengue vaccine pact
Trendlyne: Sun Pharma, ICGEB to jointly develop designer' dengue vaccine
W3 news: Su Pharma and ICGEB to develop novel dengue vaccine

19 October 2016
Business Standard: Sun Pharma & ICGEB to jointly develop dengue vaccine
Business Today: Sun Pharma ties up with genetic engineering centre to devolp dengue vaccine
Corporate Ethos: Sun Pharma, ICGEB join hand to develop new dengue vaccine
Dynamic Level: Sun Pharma collaborates with ICGEB
ET world: Sun Pharma signs deal with ICGEB to develop novel dengue vaccine
Express Pharma: Sun Pharma, ICGEB collaborate to develop novel dengue vaccine
The Financial Express: Sun Pharma signs deal with ICGEB to develop novel dengue vaccine
Hindu business: Sun Pharma, genetic research centre to develop dengue vaccine
Hindustan times: First made-inIndia dengue vaccine candidate protects against all 4 strains
Hinudstan times: Study could help create tests to diagnose patients with dengue and chikungunya
Pharmabiz: ICGEB, Sun Pharma partner to develop dengue vaccine
Pharma file: Sun Pharma to partner ICGEB to develop novel dengue treatment
Investigating.com: Sun Pharma & ICGEB enter pact to develop novel dengue vaccine for India
News now: Sun pHarma to jointly develop designer dengue vaccine
Reuters: SUN PHARMA & ICGEB enter pact to develop novel dengue vaccine
Studycrow: Sun Pharma, ICGEB tie up to develop denghe vaccine

18 October 2016
OOyuz beta: Sun Pharma & ICGEB enter pact to develop new vaccine dengue

28 September 2016
FiercePharma: Chasing Sanofi's Dengvaxia, Sun Pharma licensed dengue fever vaccine from Indian biotech lab

 

Go back

Cod. Fisc. 90031700322

AREA Science Park
Padriciano 99
34149 Trieste, ITALY
Tel: +39-040-37571
Fax: +39-040-226555
icgebicgeb.org
Address book

 

 

 

 

 

 

 

 tl_files/iTunes_Badge_Color_master_10251024.png

 

tl_files/FB.png tl_files/Twitter_logo_blue-1def.png tl_files/rss.png
tl_files/LinkedIn-InBug-2CRev2.png tl_files/YouTube.png